Angelo Gordon & Co’s TriSalus Life Sciences TLSI Stock Holding History

Angelo Gordon & Co’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,854	Closed	-$54.4K	–	67
2024 Q4	$54.4K	Sell	10,854 -10,000	-48%	-$42.3K	0.01%	49
2024 Q3	$96.1K	Buy	+20,854	New	+$110K	0.03%	53
2022 Q1	–	Sell	-181,754	Closed	-$1.8M	–	247
2021 Q4	$1.8M	Hold	181,754	–	–	0.17%	79
2021 Q3	$1.8M	Hold	181,754	–	–	0.1%	89
2021 Q2	$1.76M	Hold	181,754	–	–	0.09%	81
2021 Q1	$1.76M	Buy	+181,754	New	+$1.84M	0.15%	86

Other funds holding TLSI

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Angelo Gordon & Co's TLSI Position: Q1 2025 in Review

Angelo Gordon & Co sold out of TriSalus Life Sciences (TLSI) in Q1 2025, closing a stake of 10,854 shares — an estimated $54.4K sold.

Angelo Gordon & Co first reported a position in TLSI in Q1 2021 and held it in 6 quarters. The position peaked at $1.8M in Q3 2021. 36 funds tracked by Wall St. Rank hold TLSI as of Q1 2025.

Angelo Gordon & Co reported no remaining TriSalus Life Sciences position as of Q1 2025 after selling out during the quarter.
Angelo Gordon & Co sold 10,854 TriSalus Life Sciences shares in Q1 2025, an estimated $54.4K.
Angelo Gordon & Co first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 6 quarters.
Angelo Gordon & Co's TriSalus Life Sciences position peaked at $1.8M in Q3 2021.
36 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2025.

Based on Angelo Gordon & Co's 13F filing for Q1 2025, filed 15 May 2025.